Imiquimod Inhibitor CAS No. 99011-02-6

Cat. No.	Name	Size	Price	Add Cart
KI2148	Imiquimod	1 g	$1072
KI2148	Imiquimod	5 g	$4288

Chemical Characteristic

Product Name	Imiquimod
Synonyms	R-837, S-26308, Aldara
CAS No.	99011-02-6
Molecular Weight	240.31
Formula	C₁₄H₁₆N₄
Chemical Name	4-Amino- 1-isobutyl-1H-imidazo[4,5-c]quinoline
Smiles	n1c(c2c(c3ccccc13)n(cn2)CC(C)C)N
Chemical Structure

Biological activities

Imiquimod is a Toll-like receptor 7 (TLR-7) agonist. Imiquimod has potent anti-viral and anti-tumor properties. Imiquimod is an immune response modifier that induces the synthesis and secretion of interferon-α (INF-α), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) in a variety of cell types in vitro.^[1]^[2] Imiquimod also activates Langerhans cells, natural killer cells, macrophages and B-lymphocytes.^[3] In vitro, imiquimod treatment also induces apoptosis in all squamous cell carcinomas (SCCs) cell lines (including SCC12, SCC13, SCC15, SCL-1, and SCL-2) and HaCaT cells.^[4] In a mouse hemangioendothelioma model in vivo, imiquimod treatment significantly decreases tumor growth and increases animal survival in comparison with control mice.^[5]

Protocols

In vivo: Prior to use, imiquimod is dissolved in 0.2% DMSO and water until final concentration.^[6]

References

[1] Hemmi H, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002, 3(2): 196-200. [2] Bilu D, et al. Imiquimod: modes of action. Br J Dermatol. 2003, 149 Suppl 66: 5-8. [3] Miller RL, et al. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol. 1999, 21(1): 11-14. [4] Schön M, et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst. 2003, 95(15): 1138-1149. [5] Sidbury R, et al. Topically applied imiquimod inhibits vascular tumor growth in vivo. J Invest Dermatol. 2003, 121(5): 1205-1209. [6] Smorlesi A, et al. Imiquimod and S-27609 as adjuvants of DNA vaccination in a transgenic murine model of HER2/neu-positive mammary carcinoma. Gene Ther. 2005, 12(17): 1324-1332.

Please click here to fill online order form, and we will make sure to supply you product with detail information. This process usually takes between 24 to 48 hours, depending on products stock avaliability. All inquires and subsequent projects are handled in the strictest confidence and will be backed by a confidentiality agreement if required.